OQROGet OQRO Pro
Insider trade

Maia Biotechnology (MAIA)CEO bought ~$57K

Vlad Vitoc, CEO at Maia Biotechnology, bought ~$57K of Maia Biotechnology shares.

~$57K
Approx. value · 50K sh @ $1.14
903K
Holds after · shares reported
Traded
Nov 28, 2025
Filed
Dec 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 19, 2022InsiderDirector purchased ~$10K of MAIA shares in the open market
  2. Sep 29, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  3. Oct 13, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  4. Nov 21, 2025Insider · First buy since 2023CEO purchased ~$1.7K of MAIA shares in the open market
  5. Nov 24, 2025Insider · 2 peopleInsiders: 2 purchases (~$20K)
  6. Nov 25, 2025Insider · 3 peopleInsiders: 3 purchases (~$35K)
  7. Nov 26, 2025Insider · 3 peopleInsiders: 3 purchases (~$60K)
  8. Nov 28, 2025 · this disclosureInsider · 3 insiders in a week, 6th time since 2022CEO purchased ~$57K of MAIA shares in the open market

What came next

  1. Nov 28, 2025Insider · 3 insiders in a week, 6th time since 2022Director purchased ~$20K of MAIA shares in the open market
  2. Dec 5, 2025Insider · 1 personInsiders: 3 purchases (~$16K)
  3. Dec 16, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  4. Dec 22, 2025Insider · 3 peopleInsiders: 3 purchases (~$220K)
  5. Mar 2, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Maia Biotechnology

For Maia Biotechnology, OQRO holds 7 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MAIA page.

Other recent filings by Vlad Vitoc, Chief Executive Officer

The full history of Vlad Vitoc, Chief Executive Officer is on the profile page.

How this filing works

Other disclosures at Maia Biotechnology

Everything OQRO holds on this company is on its MAIA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data